Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SciClone Acquires China Rights for PAD Drug from Taiwan Liposome

publication date: Jun 26, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
SciClone Pharma, a US company that brings western-style drugs to China, has licensed exclusive rights to a treatment for peripheral arterial disease from Taiwan Liposome Company (TLC). The product, called ProFlow®, is a novel lipid formulation of prostaglandin E1 (PGE1), a vasodilator and platelet inhibitor. The agreement calls for up to $39.5 million in development and sales milestones. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners